132 related articles for article (PubMed ID: 37586908)
1. Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA).
Di Nardo P; Basile D; Siciliano A; Pelizzari G; Corvaja C; Buriolla S; Ongaro E; Maria Grazia D; Garattini SK; Foltran L; Guardascione M; Casagrande M; Buonadonna A; Prantera T; Aprile G; Puglisi F
Dig Liver Dis; 2024 May; 56(5):786-794. PubMed ID: 37586908
[TBL] [Abstract][Full Text] [Related]
2. Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis.
van Helden EJ; Menke-van der Houven van Oordt CW; Heymans MW; Ket JCF; van den Oord R; Verheul HMW
Cancer Metastasis Rev; 2017 Jun; 36(2):395-406. PubMed ID: 28695301
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis.
Petrelli F; Cherri S; Ghidini M; Tomasello G; Ghidini A; Zaniboni A
Dig Liver Dis; 2024 Feb; 56(2):242-247. PubMed ID: 37369616
[TBL] [Abstract][Full Text] [Related]
4. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis.
Wang H; Ma B; Gao P; Song Y; Xu Q; Hu Y; Zhang C; Wang Z
Onco Targets Ther; 2016; 9():5405-16. PubMed ID: 27621654
[TBL] [Abstract][Full Text] [Related]
6. Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis.
Zhou M; Yu P; Hou K; Fu L; Chen Y; Qu J; Qu X; Liu Y; Zhang J
Meta Gene; 2016 Sep; 9():110-9. PubMed ID: 27331015
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
8. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type
Jiang W; Yu Q; Ning R; Zhao W; Wei C
Onco Targets Ther; 2018; 11():4271-4281. PubMed ID: 30100734
[TBL] [Abstract][Full Text] [Related]
10. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
12. Optimal Sequence and Second-Line Systemic Treatment of Patients with
Wu CC; Hsu CW; Hsieh MC; Wang JH; Chang MC; Yang CS; Su YC
J Clin Med; 2021 Nov; 10(21):. PubMed ID: 34768686
[TBL] [Abstract][Full Text] [Related]
13. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
[TBL] [Abstract][Full Text] [Related]
14. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
15. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
16. First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.
Ottaiano A; De Stefano A; Capozzi M; Nappi A; De Divitiis C; Romano C; Silvestro L; Cassata A; Casaretti R; Tafuto S; Caraglia M; Berretta M; Nasti G; Avallone A
Front Pharmacol; 2018; 9():441. PubMed ID: 29773991
[No Abstract] [Full Text] [Related]
17. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
18. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
19. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Parisi A; Cortellini A; Cannita K; Venditti O; Camarda F; Calegari MA; Salvatore L; Tortora G; Rossini D; Germani MM; Boccaccino A; Dell'Aquila E; Fulgenzi C; Santini D; Tursi M; Tinari N; Marino PD; Lombardi P; Keränen SR; Álvaro MH; Zurlo IV; Corsi DC; Emiliani A; Zanaletti N; Troiani T; Vitale P; Giampieri R; Merloni F; Occhipinti MA; Marchetti P; Roberto M; Mazzuca F; Ghidini M; Indini A; Garajova I; Zoratto F; Monache SD; Porzio G; Ficorella C
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]